Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues

LIESTAL, Switzerland--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN, 'Curatis') announces a new distribution contract with Phoenix Labs (Ireland) for four products in Switzerland.

Significant revenue growth with new products

Curatis has signed a contract with Phoenix Labs (Ireland) to distribute four products in the areas of pain management and urology in Switzerland, starting from October 2025. These products generated revenues of approximately CHF 5 million in Switzerland in 2024. As the marketing authorisation holder, Curatis will be responsible for all regulatory, quality and pharmacovigilance services on behalf of Phoenix Labs in Switzerland.

About Curatis:

Curatis Holding AG is a publicly listed company (CURN.SW) specializing in the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orphan and specialist drugs. More information can be found on the website www.curatis.com.

Disclaimer:

The information contained in this media release and in any link to our website indicated herein is not for use within any country or jurisdiction or by any persons where such use would constitute a violation of law. If this applies to you, you are not authorized to access or use any such information.

This media release contains “forward-looking statements” that are based on our current expectations, assumptions, estimates and projections about us and our industry. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “may”, “will”, “should”, “continue”, “believe”, “anticipate”, “expect”, “estimate”, “intend”, “project”, “plan”, “will likely continue”, “will likely result”, or words or phrases with similar meaning. Undue reliance should not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties, including, without limitation, economic, competitive, governmental and technological factors outside of the control of Curatis Group, that may cause Curatis’ business, strategy or actual results to differ materially from the forward-looking statements (or from past results). For any factors that could cause actual results to differ materially from the forward-looking statements contained in this media release, please see the risk factors included in our listing prospectus in connection with the Business Combination. Curatis Group undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should further be noted that past performance is not a guide to future performance. Persons requiring advice should consult an independent adviser.

The information contained in this media release is not an offer to sell or a solicitation of offers to purchase or subscribe for securities. This media release is not a prospectus within the meaning of the Swiss Financial Services Act nor a prospectus under any other applicable laws.

Some financial information in this media release has been rounded and, as a result, the figures shown as totals in this media release may vary slightly from the exact arithmetic aggregation of the figures that precede them.